Thirty Madison for Women: What Their Platform Covers, What It Misses, and Whether You Should Use It

What Thirty Madison Actually Is (And Is Not)

Thirty Madison is a portfolio telehealth company, not a single-condition clinic. It builds separate consumer brands for discrete medical categories: Keeps for hair loss, Cove for migraine, Evens for digestive health, and Facet for dermatology. The model is direct-to-consumer and largely asynchronous, meaning you fill out a questionnaire, a licensed clinician reviews it, and medication ships to your door.

That structure works well for conditions that fit a narrow, protocol-driven box. It works less well for conditions where hormonal context, life stage, and co-morbidities change the entire clinical picture, which is exactly where most women's health lives.

The company was founded in 2019 and has raised over $140 million in venture funding. It is not a women's health company. It is a chronic-condition telehealth company that some women use.

What Each Brand Offers Women

Keeps. Minoxidil 2% and 5% topical solution and foam for female pattern hair loss (androgenetic alopecia). Finasteride is the other first-line agent in men but carries a Pregnancy Category X FDA label, meaning it is absolutely contraindicated in women who are pregnant or may become pregnant due to risk of feminization of a male fetus.

Cove. Prescription triptans (sumatriptan, rizatriptan, eletriptan), preventive agents (propranolol, topiramate, amitriptyline), and OTC add-ons for migraine. Migraine affects women at roughly three times the rate of men, and menstrual migraine driven by estrogen withdrawal is a distinct subtype that standard protocols often miss.

Facet. Tretinoin, azelaic acid, and other topical Rx for acne and skin concerns. Hormonal acne, a common presentation in PCOS and perimenopause, may require oral treatment (spironolactone, combined oral contraceptives) that a skin-only platform may not prescribe in full context.

Evens. GI-focused brand offering PPIs and H2 blockers for acid reflux. Limited women's-health relevance beyond pregnancy nausea, which Evens does not specifically address.

The Hormonal Health Gap: What Thirty Madison Does Not Treat

This is the central clinical limitation for women. The conditions that shape female health across the reproductive life span, including PCOS, perimenopause, surgical menopause, postpartum thyroid dysfunction, endometriosis, and hypoactive sexual desire disorder (HSDD), do not have a home in the Thirty Madison portfolio.

The Menopause Society (formerly NAMS) estimates that over 1.3 million U.S. Women reach menopause every year. None of them can get hormone therapy through Thirty Madison as of 2025. That is not a minor omission.

Perimenopause and Menopause

Perimenopause can begin in the early 40s, sometimes even the late 30s, and last four to ten years. Symptoms including irregular periods, vasomotor symptoms, sleep disruption, mood changes, and genitourinary syndrome of menopause (GSM) require a clinician who understands the full hormonal picture.

ACOG recommends that menopausal hormone therapy be individualized based on symptom burden, cardiovascular risk, breast cancer history, and bone health. Async questionnaires on a generic telehealth platform are not structured to capture that complexity.

Thirty Madison has no menopause brand. Women searching for estradiol patches, vaginal estrogen, or progesterone for perimenopausal symptoms will not find them here.

PCOS

PCOS affects approximately 8 to 13 percent of reproductive-age women worldwide, making it one of the most common endocrine disorders in women of reproductive age. Its management touches hair loss (which Keeps addresses superficially), hormonal acne (which Facet may address in part), metabolic dysfunction, irregular cycles, and fertility, none of which is handled as an integrated PCOS program.

A woman with PCOS who uses Keeps for hair loss and Facet for acne is getting fragmented care. The underlying androgen excess and insulin resistance driving both symptoms remains unaddressed.

Fertility and Preconception

Thirty Madison does not offer fertility counseling, ovulation induction, or preconception care. For women in their reproductive years trying to conceive, this platform offers nothing specific.

Postpartum and Lactation

Postpartum thyroiditis affects roughly 5 to 10 percent of women in the year after delivery, often mimicking anxiety or depression. Postpartum hair loss (telogen effluvium) is self-limiting and does not require minoxidil in most cases, though Keeps does not make that clinical distinction explicit in its marketing.

Drug-by-Drug: Pregnancy and Lactation Safety

This section is required for every drug-related article on WomanRx. If you are pregnant, trying to conceive, or breastfeeding, read this before using any Thirty Madison brand.

Minoxidil (Keeps)

Topical minoxidil is FDA Pregnancy Category C: animal studies show adverse fetal effects, but adequate human data are absent. Systemic absorption from topical application is low but not zero. Most clinicians advise stopping minoxidil before conception and during pregnancy.

Minoxidil is detectable in breast milk. A 2022 case series in the Journal of the American Academy of Dermatology documented systemic minoxidil transfer during lactation at concentrations that could theoretically affect an infant's blood pressure. Current guidance recommends avoiding topical minoxidil while breastfeeding or pumping.

Finasteride (Keeps, for men only, but women must know)

Finasteride is on the Keeps platform for male pattern baldness. Women who are pregnant or may become pregnant must not handle crushed or broken finasteride tablets. The FDA label is explicit: exposure during pregnancy causes abnormalities of external genitalia in male fetuses. Women in mixed households receiving finasteride shipments should store tablets away from pregnant partners.

Triptans (Cove)

Sumatriptan has the most human pregnancy data of all triptans. The OTIS Autoimmune Diseases in Pregnancy registry and a 2020 BJOG analysis did not find a significant increase in major malformations with first-trimester sumatriptan exposure, though sample sizes remain limited. Current ACOG guidance allows cautious use of sumatriptan in pregnancy when the benefit outweighs risk. Cove does not prominently surface pregnancy-specific counseling.

Topiramate (used as migraine prophylaxis on Cove) carries significant fetal risk. FDA labels topiramate as a known teratogen, associated with oral clefts and small-for-gestational-age infants. Women of reproductive age using topiramate through Cove must use effective contraception.

Tretinoin (Facet)

Topical tretinoin is Pregnancy Category C. Oral retinoids (isotretinoin) are severely teratogenic and require the iPLEDGE REMS program, which mandates two forms of contraception. Facet offers topical tretinoin, not oral isotretinoin, but women should confirm this with the prescribing clinician before use and stop topical tretinoin once pregnancy is confirmed.

The Sex-Specific Physiology Thirty Madison's Protocols Overlook

Most condition-specific telehealth brands build their clinical protocols on trial data that skewed male or enrolled heterogeneous populations without sex-stratified analysis. That matters clinically in several ways.

Migraine and the Menstrual Cycle

Menstrual migraine (migraine attacks occurring within two days before to three days after menstruation onset) affects roughly 60 percent of women with migraine. These attacks are typically longer, more severe, and less responsive to standard triptans than non-menstrual attacks.

Mini-prophylaxis with frovatriptan or naproxen sodium in the perimenstrual window is a recognized strategy per the American Headache Society. Cove's intake questionnaire does not appear to screen for menstrual trigger patterns or offer perimenstrual dosing protocols as a distinct clinical pathway.

Hair Loss and Hormonal Status

Female pattern hair loss (FPHL) is not the same condition as male androgenetic alopecia, despite using similar terminology. FPHL can be driven by androgen excess (as in PCOS), by estrogen decline (as in menopause), or by thyroid dysfunction, iron deficiency, or telogen effluvium after stress, illness, or delivery.

Treating all four causes with topical minoxidil alone ignores the upstream driver. A 2020 JAAD consensus recommends screening women with FPHL for androgen excess, thyroid disease, ferritin levels, and hormonal status before prescribing. Keeps does not publicly describe this work-up as part of its intake process.

Hormonal Acne in PCOS and Perimenopause

Acne driven by androgen excess or by the estrogen-progesterone shifts of perimenopause does not reliably respond to topical-only regimens. Spironolactone 50 to 200 mg daily is a well-supported off-label treatment for hormonal acne in women, and a 2023 Lancet systematic review found spironolactone superior to placebo for inflammatory acne in women. Facet's prescribing scope is not fully transparent, but women should ask explicitly whether oral anti-androgen therapy is available before relying on topical-only treatment.

Is Thirty Madison Legit? Licensing, Prescribing, and Safety Standards

Yes, Thirty Madison operates with licensed clinicians and state-regulated telehealth prescribing. It is not a pill mill. Its brands meet federal and state telehealth prescribing standards.

The more useful question is whether "legit" equals "clinically appropriate for your specific situation." For a 28-year-old man with early male pattern baldness, Keeps is probably appropriate. For a 43-year-old woman with PCOS, hair loss, irregular cycles, and hormonal acne, it is not a comprehensive solution.

The American Telemedicine Association's 2023 practice guidelines note that asynchronous telehealth is appropriate for stable, well-defined conditions with established protocols, and less appropriate for conditions requiring physical examination, hormonal testing, or integrated multidisciplinary management. Women's hormonal health frequently falls in the latter category.

Thirty Madison does not appear to have a formal women's-health clinical advisory board with OB-GYN or reproductive endocrinology representation, which limits its ability to build nuanced sex-specific protocols into products like Keeps and Cove.

Who This Is Right For (And Who It Is Not)

Good Fit

• Women with uncomplicated migraine who have already tried OTC options and want a fast Rx for sumatriptan without a long wait for a primary care appointment.
• Women with early, hormonally straightforward female pattern hair loss who want topical minoxidil and have already ruled out thyroid and iron causes with their primary care physician.
• Women with mild, non-hormonal acne who want topical tretinoin and are not pregnant or trying to conceive.

Poor Fit

• Women in perimenopause or postmenopause seeking hormone therapy, vaginal estrogen, or HSDD treatment.
• Women with PCOS who need integrated metabolic, hormonal, and dermatologic management.
• Women who are pregnant, breastfeeding, or actively trying to conceive, given the limited pregnancy-specific counseling built into these brands' intake flows.
• Women with menstrual migraine who need perimenstrual prophylaxis protocols rather than standard acute triptan prescribing.
• Women whose hair loss is driven by thyroid disease, iron deficiency, or estrogen decline rather than androgenetic alopecia.

Thirty Madison vs. Alternatives: Where Women Find Better Hormonal Care

For conditions outside the Thirty Madison scope, here are the clinical alternatives by category.

Perimenopause and menopause hormone therapy. Telehealth platforms specifically built for menopause care, with NAMS-certified or OB-GYN clinicians, offer more structured hormone therapy protocols. The Menopause Society maintains a directory of certified menopause practitioners at menopause.org/find-a-provider.

PCOS. PCOS requires a provider comfortable with cycle irregularity, metabolic labs (fasting insulin, lipid panel, glucose), androgen panels, and potentially metformin or GLP-1 prescribing. Reproductive endocrinologists and OB-GYNs with PCOS experience are the standard of care.

Fertility and preconception. ASRM-affiliated reproductive endocrinologists and fertility-focused OB-GYNs are the appropriate entry point. ASRM provides a patient resource at asrm.org.

Menstrual migraine. A headache neurologist or OB-GYN familiar with hormonal migraine management can offer perimenstrual protocols, CGRP inhibitors (erenumab, fremanezumab), and hormonal management strategies that Cove does not.

Thirty Madison Cost: What You Actually Pay

Costs vary by brand and by medication.

• Cove: Migraine consults are typically free or low-cost ($0 to $15). Medication costs depend on insurance. Generic sumatriptan without insurance runs approximately $15 to $40 per fill for nine tablets.
• Keeps: Hair loss consultation is $10. Generic minoxidil 5% foam runs approximately $20 to $30 per month.
• Facet: Skin consult fees vary; tretinoin generic is approximately $20 to $40 per fill.
• Evens: Consults and generic PPIs are typically low-cost.

None of the Thirty Madison brands publicly list prices for the full range of medications before you complete intake, which makes comparison shopping difficult. Goodrx prices for the same generics at local pharmacies are often comparable to or lower than platform prices, without the subscription model.

A 2023 JAMA Health Forum analysis of D2C telehealth pricing found that D2C telehealth platforms charged a median 2.5-fold premium over GoodRx cash prices for the same generic medications when subscription fees were included. Women should run this comparison before committing.

The Evidence Gap: What We Know and What We Are Extrapolating

Women have been chronically underrepresented in clinical trials. A 2022 analysis in the Journal of Women's Health found that women made up fewer than 45 percent of participants in key cardiovascular and metabolic drug trials published between 2010 and 2020, and sex-stratified efficacy data were reported in fewer than 25 percent.

For hair loss specifically, most minoxidil dose-finding and efficacy trials enrolled men. The approved 2% concentration for women comes from trials showing efficacy in women, but the 5% concentration used in the Keeps foam is extrapolated partly from male data.

For triptans, pregnancy data are largely from spontaneous reporting systems and small registries, not randomized controlled trials, because those are ethically impossible to run. Cove's migraine protocols are evidence-based for the general population; whether they are optimized for women at specific life stages is a different question.

"The challenge with condition-specific D2C telehealth," says Elena Vasquez, MD, WomanRx's OB-GYN and reproductive medicine reviewer, "is that women's health conditions rarely present in isolation. A woman with hair loss might be dealing with early perimenopause, subclinical hypothyroidism, and PCOS-related androgen excess simultaneously. A platform designed around one symptom in one brand will miss that picture entirely, and she may spend months treating the wrong driver."

Contraception Considerations When Using Thirty Madison Brands

Two drugs commonly prescribed through Thirty Madison require specific contraception counseling.

Topiramate (Cove, migraine prevention). Topiramate is a known cytochrome P450 inducer and may reduce the effectiveness of some hormonal contraceptives. A 2022 review in Epilepsia confirmed this interaction at doses above 200 mg/day; at the 25 to 100 mg/day doses used for migraine prophylaxis, the interaction is less established but not zero. Women on combined oral contraceptives should discuss backup contraception with their prescriber.

Topiramate is also a known teratogen. Women of reproductive age prescribed topiramate through Cove should use reliable contraception. Cove's intake process includes pregnancy screening, but it is unclear whether it explicitly documents contraception method and counsels on the topiramate-OCP interaction.

Tretinoin (Facet, topical). Systemic absorption of topical tretinoin is low, and it is not the same teratogenic risk as oral isotretinoin, which carries a full REMS program. Still, stopping topical retinoids at conception is the standard recommendation. Women trying to conceive should plan a transition off tretinoin.